Longitudinal Cytokine Profile in Patients With Mild to Critical COVID-19

Abstract

The cytokine release syndrome has been proposed as the driver of inflammation in coronavirus disease 2019 (COVID-19). However, studies on longitudinal cytokine profiles in patients across the whole severity spectrum of COVID-19 are lacking. In this prospective observational study on adult COVID-19 patients admitted to two Hong Kong public hospitals, cytokine profiling was performed on blood samples taken during early phase (within 7 days of symptom onset) and late phase (8 to 12 days of symptom onset). The primary objective was to evaluate the difference in early and late cytokine profiles among patient groups with different disease severity. The secondary objective was to assess the associations between cytokines and clinical endpoints in critically ill patients. A total of 40 adult patients (mild = 8, moderate = 15, severe/critical = 17) hospitalized with COVID-19 were included in this study. We found 22 cytokines which were correlated with disease severity, as proinflammatory Th1-related cytokines (interleukin (IL)-18, interferon-induced protein-10 (IP-10), monokine-induced by gamma interferon (MIG), and IL-10) and ARDS-associated cytokines (IL-6, monocyte chemoattractant protein-1 (MCP-1), interleukin-1 receptor antagonist (IL-1RA), and IL-8) were progressively elevated with increasing disease severity. Furthermore, 11 cytokines were consistently different in both early and late phases, including seven (growth-regulated oncogene-alpha (GRO-α), IL-1RA, IL-6, IL-8, IL-10, IP-10, and MIG) that increased and four (FGF-2, IL-5, macrophage-derived chemokine (MDC), and MIP-1α) that decreased from mild to severe/critical patients. IL-8, followed by IP-10 and MDC were the best performing early biomarkers to predict disease severity. Among critically ill patients, MCP-1 predicted the duration of mechanical ventilation, highest norepinephrine dose administered, and length of intensive care stay.

Gender Differences Associated with the Prognostic Value of BPIFB4 in COVID-19 Patients: A Single-Center Preliminary Study

“…Unbalanced pro-inflammatory cytokine secretion is associated with COVID-19 severity and mortality [ 31 ]. To assess whether a hyperinflammatory state could show different results in male and female patients, we performed a multiplex bead-based immunoassay on plasma from high-grade and low-grade patients (for both female and male).…”

Preclinical In Silico Evidence Indicates the Pharmacological Targets and Mechanisms of Mogroside V in Patients With Ovarian Cancer and Coronavirus Disease 2019

“…In clinical observation, cytokine profiling in patients with a severity spectrum of COVID-19 has been characterised ( 24 ). Cytokine storm is related to an increased death rate in patients with COVID-19, and the suppression of cytokine-induced injury may be the screening parameter of effective COVID-19 drugs ( 25 ).…”

Contemporary Concise Review 2021: COVID‐19 and other respiratory infections

“…Cytokine dysregulation has been proposed as the driver of inflammation. Among critically ill patients, monocyte chemoattractant protein‐1 predicted the duration of mechanical ventilation, highest norepinephrine dose administered and length of ICU stay 31 …”